Paraganglioma Market Research Report- Forecast till 2027

Paraganglioma Market Research Report, By Type (Caroid Paragangliomas, Cervical, Secretory, Temporal, And Vagal Paragangliomas), Treatment (Therapeutic, Diagnostic), End Users (Hospital, Ambulatory Centers, Oncology Centers) - Forecast Till 2027

ID: MRFR/Pharma/3411-HCR | | Region: Global | 85 pages

Paraganglioma Market Scenario:

A paraganglioma or glomus tumors is a rare type of cancer occurs in a variety of places in the head and neck. The tumor begins in certain nerve cells that are distributed throughout the body. Paragangliomas affect at any age and over half of the paragangliomas appear in the temporal bone. Similar to other types of cancer, paragangliomas is very difficult to diagnose in early stages as the tumor is often slow growing and noncancerous (benign). However, it can invade other/ nearby organ and part of the body, and become cancerous and spread distantly. Though a number of diagnostic and therapeutic treatments are available in the market, none of them are that effective for the treatment and diagnostic. According to the research carried out by Florida Hospital System (2014), 1-2 patient in a million develops paragangliomas. According to cancer research the UK in 2012, globally over 14.1 million of new cancer cases were registered. The treatment for all types of cancer are nearly similar, thus, increasing prevalence of cancer has boosted the development of the new treatments. Increasing number of patients suffering from paragangliomas and continuous advances in the treatment have driven the growth of the market. Additionally, deteriorating lifestyle due to alcoholism and smoking, increasing healthcare expenditure, and increasing government support for research & development have fuelled the market growth. A number of treatment are available in the market, however, nearly all the treatment show some or other adverse effects on the body. Additionally, high cost of the treatment and side effects of the therapy may slow the growth of the market during the forecasted period.

The global paraganglioma market is expected to grow at a CAGR of ~6.1 % during the forecast period 2017-2023.

 Figure 1- Market Synopsis of the Global Paraganglioma Market Research, by Region, 2016 (%) Paraganglioma Market


Sources- WHO, cancer research UK, American Cancer Society


Segmentation


The global paraganglioma market is segmented on the basis of types, treatment, and end users.


On the basis of types, the market is segmented into caroid paraganglioma, cervical paraganglioma, jugular paraganglioma, secretory paraganglioma, temporal paraganglioma, vagal paraganglioma, and others.


On the basis of the treatment, the market is categorized into therapeutic treatment and diagnostic treatment. The therapeutic treatment is further segmented into surgery, embolization, and radiotherapy. The embolization is further categorized into liquid embolic agents, sclerosing agents, particulate embolic agents, and others. The radiotherapy is sub-segmented into external beam radiation therapy, brachytherapy, and unsealed source radiotherapy. The diagnostic treatments are further segmented into CT scans, MRI, angiography, blood test, and others.


On the basis of the end users, the market is segmented into hospital & clinics, ambulatory care centers, and others. 


Regional Analysis


The Americas account for the major share of the global paraganglioma market owing to the increasing prevalence of paragangliomas, well-developed technology and increasing government support for research & development. Moreover, high healthcare expenditure and changing lifestyle have fuelled the growth of the Americas paraganglioma market. The concentration of major players in this region is likely to support the growth of the market during the forecasted period.


Europe holds the second largest paraganglioma market, which is followed by Asia Pacific. Availability of the funds for research & development and strong government support have driven the market growth. Asia Pacific is the fastest growing paraganglioma market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support.


On the other hand, the Middle East & Africa hold the least share of the market due to poor political conditions in Africa and limited availability of funds and availability of medical facilities. The Middle East dominates the Middle East & Africa Paraganglioma market due to the presence of well-developed countries like Kuwait, Qatar, Oman and South Arabia. Whereas, Africa region is expecting a healthy growth due to the presence of huge opportunity for the development of the market.


Market Assessment Global Paraganglioma Market


Sources- WHO, cancer research UK, American Cancer Society


 


Key Players in Global Paraganglioma Market


Some of key the players in the market are Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (U.S.), Amgen, Inc. (U.S.),  Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Immunomedics (U.S.),and Oncomed Pharmaceuticals (U.S.).


Intended Audience



  • Pharmaceutical Companies

  • Government and private research companies

  • Research and Development (R&D) Companies

  • Drug Manufacturers and Suppliers

  • Medical Research Laboratories


 



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2017-2023: 5.1%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, treatment, and end users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (U.S.), Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Immunomedics (U.S.),and Oncomed Pharmaceuticals (U.S.)
  Key Market Opportunities

  • Government support for research & development
  • High healthcare expenditure and changing lifestyle
  •   Key Market Drivers   Increasing number of patients suffering from paragangliomas and continuous advances in the treatment


    Frequently Asked Questions (FAQ) :


    paraganglioma market CAGR would be 6.1% during the forecast period.

    paraganglioma market restraint would be its high cost of treatment.

    The Americas would take the lead of the paraganglioma market.

    The Asia Pacific paraganglioma market would be the fastest-growing one.

    The treatment types included in the paraganglioma market report are therapeutic treatment and diagnostic treatment.

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Paraganglioma Market, by Types

    6.1 Introduction

    6.2 Caroid Paraganglioma

    Market Estimates & Forecast, 2020 – 2027

    6.3 Cervical Paraganglioma

    Market Estimates & Forecast, 2020 – 2027

    6.4 Jugular Paraganglioma

    Market Estimates & Forecast, 2020 – 2027

    6.5 Secretory Paraganglioma

    Market Estimates & Forecast, 2020 – 2027

    6.6 Temporal Paraganglioma

    Market Estimates & Forecast, 2020 – 2027

    6.7 Vagal Paraganglioma

    Market Estimates & Forecast, 2020 – 2027

    6.8 Others

    Chapter 7. Global Paraganglioma Market, by Treatment

    7.1 Introduction

    7.2 Therapeutic Treatment

    Market Estimates & Forecast, 2020 – 2027

    7.2.1 Surgery

    7.2.1.1 Embolization

    7.2.1.1.1 Liquid Embolic Agents

    7.2.1.1.2 Sclerosing Agents

    7.2.1.1.3 Particulate Embolic Agents

    7.2.1.1.4 Others

    7.2.1.2 Radiotherapy

    7.2.1.2.1 External Beam Radiation Therapy

    7.2.1.2.2 Brachytherapy

    7.2.1.2.3 Unsealed Source Radiotherapy

    7.3 Diagnostic Treatment

    Market Estimates & Forecast, 2020 – 2027

    7.4.1 CT Scans

    7.4.2 MRI

    7.4.3 Angiography

    7.4.4 Blood Test

    7.4.5 Others

    Chapter 8 Global Paraganglioma Market, by End User

    8.1 Introduction

    8.2 Hospital & Clinics

    Market Estimates & Forecast, 2020 – 2027

    8.3 Ambulatory Care Centers

    Market Estimates & Forecast, 2020 – 2027

    8.4 Others

    Chapter 9. Global Paraganglioma Market, by Region

    9.1 Introduction

    9.2 America

    9.2.1 North America

    9.2.1.1 US

    9.2.1.1 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 UK

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia Pacific

    9.5 The Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of the Middle East & Africa

    Chapter 10 Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    Chapter 11 Company Profiles

    11.1 Bristol-Myers Squibb Company

    11.1.1 Company Overview

    11.1.2 Product Overview

    11.1.3 Financials

    11.1.4 SWOT Analysis

    11.2 GlaxoSmithKline Plc.

    11.2.1 Company Overview

    11.2.2 Product Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 Bayer AG

    11.3.1 Company Overview

    11.3.2 Product Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Novartis AG

    11.4.1 Company Overview

    11.4.2 Product/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Spectrum Pharmaceuticals Inc.

    11.5.1 Company Overview

    11.5.2 Product Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.6 Amgen, Inc.

    11.6.1 Company Overview

    11.6.2 Product Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.7 Eli Lilly and Company

    11.7.1 Overview

    11.7.2 Product Overview

    11.7.3 Financial

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 Others

    Chapter 12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s View Point

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Prediction of Pharmaceutical industry

    Chapter 13 Appendix

    LIST OF TABLES

    Table 1 Paraganglioma Industry Synopsis, 2020 – 2027

    Table 2 Global Paraganglioma Market Estimates and Forecast, 2020 – 2027, (USD Million)

    Table 3 Global Paraganglioma Market by Region, 2020 – 2027, (USD Million)

    Table 4 Global Paraganglioma Market by Types, 2020 – 2027, (USD Million)

    Table 5 Global Paraganglioma Market by Treatment, 2020 – 2027, (USD Million)

    Table 6 Global Paraganglioma Market by End Users, 2020 – 2027, (USD Million)

    Table 7 North America Paraganglioma Market by Types, 2020 – 2027, (USD Million)

    Table 8 North America Paraganglioma Market by Treatment, 2020 – 2027, (USD Million)

    Table 9 North America Paraganglioma Market by End Users, 2020 – 2027, (USD Million)

    Table 10 US Market by Types, 2020 – 2027, (USD Million)

    Table 11 US Paraganglioma Market by Treatment, 2020 – 2027, (USD Million)

    Table 12 US Paraganglioma Market by End Users, 2020 – 2027, (USD Million)

    Table 13 Canada Market by Types, 2020 – 2027, (USD Million)

    Table 14 Canada Paraganglioma Market by Treatment, 2020 – 2027, (USD Million)

    Table 15 Canada Paraganglioma Market by End Users, 2020 – 2027, (USD Million)

    Table 16 South America Market by Types, 2020 – 2027, (USD Million)

    Table 17 South America Paraganglioma Market by Treatment, 2020 – 2027, (USD Million)

    Table 18 South America Paraganglioma Market by End Users, 2020 – 2027, (USD Million)

    Table 19 Europe Market by Types, 2020 – 2027, (USD Million)

    Table 20 Europe Paraganglioma Market by Treatment, 2020 – 2027, (USD Million)

    Table 21 Europe Paraganglioma Market by End Users, 2020 – 2027, (USD Million)

    Table 22 Western Europe Market by Types, 2020 – 2027, (USD Million)

    Table 23 Western Europe Paraganglioma Market by Treatment, 2020 – 2027, (USD Million)

    Table 24 Western Europe Paraganglioma Market by End Users, 2020 – 2027, (USD Million)

    Table 25 Eastern Europe Market by Types, 2020 – 2027, (USD Million)

    Table 26 Eastern Europe Paraganglioma Market by Treatment, 2020 – 2027, (USD Million)

    Table 27 Eastern Europe Paraganglioma Market by End Users, 2020 – 2027, (USD Million)

    Table 28 Asia Pacific Market by Types, 2020 – 2027, (USD Million)

    Table 29 Asia Pacific Paraganglioma Market by Treatment, 2020 – 2027, (USD Million)

    Table 30 Asia Pacific Paraganglioma Market by End Users, 2020 – 2027, (USD Million)

    Table 31 Middle East & Africa Market by Types, 2020 – 2027, (USD Million)

    Table 32 Middle East & Africa Paraganglioma Market by Treatment, 2020 – 2027, (USD Million)

    Table 33 Middle East & Africa Paraganglioma Market by End Users, 2020 – 2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Paraganglioma Market

    Figure 3 Segmentation Market Dynamics for Global Paraganglioma Market

    Figure 4 Global Paraganglioma market Share, by Type 2020

    Figure 5 Global Paraganglioma market Share, by Treatment 2020

    Figure 6 Global Paraganglioma Market Share, by End Users, 2020

    Figure 7 Global Paraganglioma Market Share, by Region, 2020

    Figure 8 North America Paraganglioma Market Share, by Country, 2020

    Figure 9 Europe Paraganglioma Market Share, by Country, 2020

    Figure 10 Asia Pacific Paraganglioma Market Share, by Country, 2020

    Figure 11 Middle East & Africa Paraganglioma Market Share, by Country, 2020

    Figure 12 Global Paraganglioma Market: Company Share Analysis, 2020 (%)

    Figure 13 Bristol-Myers Squibb Company: Key Financials

    Figure 14 Bristol-Myers Squibb Company: Segmental Revenue

    Figure 15 Bristol-Myers Squibb Company: Geographical Revenue

    Figure 16 GlaxoSmithKline Plc..: Key Financials

    Figure 17 GlaxoSmithKline Plc..: Segmental Revenue

    Figure 18 GlaxoSmithKline Plc..: Geographical Revenue

    Figure 19 Bayer AG: Key Financials

    Figure 20 Bayer AG: Segmental Revenue

    Figure 21 Bayer AG: Geographical Revenue

    Figure 22 Novartis AG: Key Financials

    Figure 23 Novartis AG: Segmental Revenue

    Figure 24 Novartis AG: Geographical Revenue

    Figure 25 Spectrum Pharmaceuticals Inc.: Key Financials

    Figure 26 Spectrum Pharmaceuticals Inc.: Segmental Revenue

    Figure 27 Spectrum Pharmaceuticals Inc.: Geographical Revenue

    Figure 28 Amgen, Inc.: Key Financials

    Figure 29 Amgen, Inc.: Segmental Revenue

    Figure 30 Amgen, Inc.: Geographical Revenue

    Figure 31 Eli Lilly and Company: Key Financials

    Figure 32 Eli Lilly and Company: Segmental Revenue

    Figure 33 Eli Lilly and Company: Geographical Revenue